ARCHIVES

FOLFOX 4 Should Be First-Line Therapy For Advanced Disease, NCCTG Finds

This article is from The Cancer Letter archive.

Vol. 26 No. 12 | December 26, 2003

Download PDF Visit The Full Archive

Related Articles

ASCO Releases Guideline On Use Of Growth Factors

May 26, 2006

NCI Advisors Approve Expansion Of CCOPs, Minority-Based CCOPs; Approve Reissuance Of BMT Network RFA, RFPs For Preclinical Drug Studies

November 13, 2009

Enzalutamide Reduced Risk of Progression By 81 Percent in Metastatic Prostate Cancer

June 27, 2014

USC $2.5 Million contract Tops Last Minute FY 75 Rush of Awards

July 18, 1975

Burton’s Clinic Reopens; Some Insurers Reportedly Reimbursing; New York Congressman Calls For Evaluation

March 28, 1986

Totality Of Evidence Causes Concern About New Findings.

December 7, 2007